| 1.1 Improvement of clinical symptoms at up to 7 days (assessed by need for respiratory support) |
1 |
103 |
Risk Ratio (M‐H, Random, 95% CI) |
0.98 [0.30, 3.19] |
| 1.2 Improvement of clinical symptoms at 8 to 15 days (assessed by need for respiratory support) |
1 |
103 |
Risk Ratio (M‐H, Random, 95% CI) |
1.85 [0.91, 3.77] |
| 1.3 Improvement of clinical symptoms at 16 to 30 days (assessed by need for respiratory support) |
1 |
103 |
Risk Ratio (M‐H, Random, 95% CI) |
1.20 [0.80, 1.81] |
| 1.4 Improvement of clinical symptoms at up to 7 days (assessed by need for respiratory support): subgroup severity of disease |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.4.1 Severe disease |
1 |
45 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.18, 2.85] |
| 1.4.2 Life‐threatening disease |
1 |
58 |
Risk Ratio (M‐H, Random, 95% CI) |
2.00 [0.19, 20.86] |
| 1.5 Improvement of clinical symptoms at 8 to 15 days (assessed by need for respiratory support): subgroup severity of disease |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.5.1 Severe disease |
1 |
45 |
Risk Ratio (M‐H, Random, 95% CI) |
2.23 [1.05, 4.76] |
| 1.5.2 Life‐threatening disease |
1 |
58 |
Risk Ratio (M‐H, Random, 95% CI) |
1.00 [0.22, 4.55] |
| 1.6 Improvement of clinical symptoms at 16 to 30 days (assessed by need for respiratory support): subgroup severity of disease |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 1.6.1 Severe disease |
1 |
45 |
Risk Ratio (M‐H, Random, 95% CI) |
1.34 [0.98, 1.83] |
| 1.6.2 Life‐threatening disease |
1 |
58 |
Risk Ratio (M‐H, Random, 95% CI) |
0.86 [0.33, 2.24] |
| 1.7 30‐day mortality |
1 |
101 |
Risk Ratio (M‐H, Random, 95% CI) |
0.65 [0.29, 1.46] |
